Search results for "amine"

showing 10 items of 7299 documents

Plasma catecholamine and serum testosterone responses to four units of resistance exercise in young and adult male athletes.

1998

The plasma noradrenaline (NA) and adrenaline (A) concentration responses of seven young male athletes [15 (SD 1) years] and seven adult male athletes [25 (SD 6) years] were investigated together with the serum testosterone (Tes) concentration responses in four different half-squatting exercises. The loads, number of repetitions, exercise intensity and recovery between the sets were manipulated such that different types of metabolic demand could be expected. However, the amount of work done was kept equal in each kind of exercise. After the most exhausting unit of exercise (E3; two sets of 30 repetitions with 50% of 1 repetition maximum and with 2-min recovery between the sets) the plasma NA…

AdultMalemedicine.medical_specialtyAgingSympathetic Nervous SystemSports medicineAdolescentEpinephrineWeight LiftingPhysiologymedicine.drug_classPhysical exerciseNorepinephrineHeart RatePhysiology (medical)Internal medicinemedicineHumansOrthopedics and Sports MedicineTestosteroneLactic AcidExercise physiologyExerciseTestosteronebiologyAthletesbusiness.industryPublic Health Environmental and Occupational HealthGeneral Medicinebiology.organism_classificationAndrogenEndocrinologyMuscle FatigueCatecholamineExercise intensityExercise Testbusinessmedicine.drugEuropean journal of applied physiology and occupational physiology
researchProduct

Incidence of postoperative nausea and vomiting (PONV) after general pre-anaesthetic prophylaxis with antihistamines

2004

AdultMalemedicine.medical_specialtyAllergyNeurologyVomitingAnesthetics GeneralImmunologyPharmacology toxicologyConscious SedationInternal medicinemedicineHumansAgedPharmacologybusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseaseRheumatologyAnesthesiaPostoperative Nausea and VomitingHistamine H1 AntagonistsFemalemedicine.symptombusinessPostoperative nausea and vomitingInflammation Research
researchProduct

Late reactions to patch test preparations with reduced concentrations of p-phenylenediamine : a multicentre investigation of the German Contact Derma…

2011

Background. p-Phenylenediamine (PPD) 1% in petrolatum has been shown in a prospective study to elicit late reactions in 1.5% of routine patch tests, which may be indicative of patch test sensitization. Objectives. To assess the frequency of late reactions to reduced PPD patch test concentrations. Methods. In 1838 patients, PPD was tested at three concentrations (0.5% pet., group I; 0.4% pet., group II; and 0.35% pet., group III). Patch tests were read on D1 (D2) to D3 (D4); additional late readings were performed on D7, D14, and D21. Patients who were not able to return for all scheduled late readings were telephoned on D7, D14, and D21, and questioned about a reaction at the patch test sit…

AdultMalemedicine.medical_specialtyAllergyTime FactorsMedizinDermatologyPhenylenediaminesGastroenterology030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineImmunopathologyInternal medicineImmunology and AllergyMedicineHumans030212 general & internal medicineProspective cohort studySensitizationbusiness.industryPatch testp-PhenylenediamineMiddle AgedPatch Testsmedicine.disease3. Good healthSurgerymedicine.anatomical_structurechemistryPatch test sensitizationDermatitis Allergic ContactFemalebusinessContact dermatitis
researchProduct

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease

1992

A randomized, placebo-controlled multicenter trial was conducted to evaluate the efficacy and safety of a delayed-release formulation of 5-aminosalicylic acid (5-ASA) (Asacol; GiulianiBracco, Milan, Italy) for prevention of clinical relapse in 125 patients with inactive Crohn's disease. Patients in remission [Crohn's Disease Activity Index (CDAI) less than 150] between 3 months and 2 years were randomly allocated to receive either 800 mg 5-ASA three times daily (n = 64) or placebo (n = 61) for up to 12 months or until relapse of symptoms. Relapse was defined by a CDAI greater than 150, with a minimum increase of 100 points over the baseline value. The cumulative relapse rates were 12% in th…

AdultMalemedicine.medical_specialtyAminosalicylic acidAdolescentmedicine.medical_treatmentPlaceboGastroenterologychemistry.chemical_compoundCrohn DiseaseInternal medicineMulticenter trialHumansMedicineIleitisMesalamineAdverse effectAgedCrohn's diseaseHepatologybusiness.industryGastroenterologyBowel resectionMiddle AgedPrognosismedicine.diseaseConfidence intervalSurgeryAminosalicylic AcidschemistryPatient ComplianceFemalebusinessGastroenterology
researchProduct

Apomorphine-Induced Growth Hormone Response Is Attenuated by Ethanol but Not Dextromethorphan

2007

Background: Misuse of alcohol drinking is a major health problem. Alcohol decreases spontaneous growth hormone (GH) secretion, but the mechanism is unclear. The aim of this study was to test whether administration of alcohol (study 1) or a N-methyl d-aspartate (NMDA) receptor antagonist (study 2) attenuates the GH response to pharmacological dopaminergic stimulation. Methods: The 2-session repeated measures design was conducted at the endocrine laboratory at the Department of Psychiatry at the Free University Berlin. Twenty healthy Caucasian males aged 35±10 years without a history of alcohol use disorders were tested using the Apomorphine (APO) challenge test. In study 1, we injected APO (…

AdultMalemedicine.medical_specialtyApomorphineMedicine (miscellaneous)PharmacologyToxicologyPlaceboDextromethorphanReceptors N-Methyl-D-Aspartatechemistry.chemical_compoundOral administrationInternal medicinemedicineHumansEthanolEthanolHuman Growth Hormonebusiness.industryDopaminergicCentral Nervous System DepressantsDextromethorphanGrowth hormone secretionApomorphinePsychiatry and Mental healthEndocrinologychemistryArea Under CurveDopamine AgonistsNMDA receptorbusinessmedicine.drugAlcoholism: Clinical and Experimental Research
researchProduct

Compliance to therapy with Dapoxetine in patients affected by Premature Ejaculation

2012

Introduction Premature ejaculation (PE) is a sexual dysfunction with high prevalence. According to some reports, it is present in about 20-30% of the male population. Since 2009 PE has been treated with a novel inhibitor of serotonin re-uptake, Dapoxetine, which has been reported to be specifically active for PE. Materials and Methods 59 patients have been selected among the patients affected by PE observed at the outpatient department of Urology and Andrology of the “Paolo Giaccone” University Policlinic Hospital of Palermo. Diagnosis was confirmed unequivocally in all patients, who were suitable for drug treatment and accepted to participate in the study. They were divided in 2 groups: on…

AdultMalemedicine.medical_specialtyBenzylaminespremature ejaculation dapoxetine Cytalopram compliance side effectsAdolescentGastrointestinal DiseasesMigraine DisordersComorbidityCitalopramCitalopramNaphthalenesMedication AdherenceSettore MED/24 - UrologiaDrug treatmentYoung AdultInternal medicineSurveys and QuestionnairesPremature ejaculationmedicineOutpatient clinicHumansIn patientPremature EjaculationEiaculazione precoce dapoxetina citalopram compliance effetti collateraliLife StyleAgedGynecologyHigh prevalencebusiness.industryGeneral MedicineMiddle AgedPatient Acceptance of Health CareDapoxetineSexual dysfunctionmedicine.symptomNervous System DiseasesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct

Reward anticipation revisited- evidence from an fMRI study in euthymic bipolar I patients and healthy first-degree relatives.

2017

Abstract Background Symptomatic phases in bipolar disorder (BD) are hypothesized to result from a hypersensitive behavioral activation system (BAS) being sensitive to potential rewards. However, studies on the neuronal underpinnings of reward anticipation in BD are scarce with contradictory findings and possibly confounded by effects of dopaminergic medication, necessitating further research on dysfunctional motivation in BD. Moreover, its role as vulnerability marker for BD is unclear. Methods Functional imaging was conducted in 16 euthymic BD-I patients free from dopaminergic medication and 19 healthy first-degree relatives using a monetary incentive delay task and compared to parallelize…

AdultMalemedicine.medical_specialtyBipolar DisorderGyrus Cinguli03 medical and health sciences0302 clinical medicineRewardmedicineHumansFamilyBipolar disorderFirst-degree relativesPsychiatryAnterior cingulate cortexMotivationVentral striatumDopaminergicBehavioral activationmedicine.diseaseAnticipationMagnetic Resonance Imaging030227 psychiatryFunctional imagingPsychiatry and Mental healthClinical Psychologymedicine.anatomical_structureFemalePsychologypsychological phenomena and processes030217 neurology & neurosurgeryClinical psychologyJournal of affective disorders
researchProduct

Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders.

2012

Whether responses to antidepressants differ in bipolar and unipolar depression remains unresolved.We analyzed patient characteristics and outcomes of antidepressant treatment of 1036 depressed patients with bipolar-I or bipolar-II disorder, or unipolar major depression, using bivariate and multivariate methods and survival analysis, testing the hypothesis that responses would be superior in unipolar depression.Antidepressants were given to 84.8% (878/1036) of depressed patients: 58.9% of 93 bipolar-I, 80.1% of 117 bipolar-II, and 91.3% of 668 unipolar disorder cases. The 158 not given antidepressants had more manias/year, spent more months in mania and depression, and were far more likely t…

AdultMalemedicine.medical_specialtyBipolar DisorderMonoamine Oxidase InhibitorsAntidepressive Agents Tricyclicbehavioral disciplines and activitiesInternal medicinemental disordersmedicineHumansBipolar disorderPsychiatrySurvival analysisDepression (differential diagnoses)Depressive Disorder MajorManic MoodMiddle Agedmedicine.diseaseAntidepressive AgentsPsychiatry and Mental healthMoodTreatment OutcomeMajor depressive disorderAntidepressantFemalemedicine.symptomPsychologyManiaSelective Serotonin Reuptake InhibitorsActa psychiatrica Scandinavica
researchProduct

[123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects

1997

[123I]Iodobenzamide (IBZM) is an iodine-labeled dopamine receptor ligand and can be used to visualize brain D2 receptors in humans with single photon emission computerized tomography (SPECT). The ratio of striatal IBZM uptake to uptake in frontal cortex (ST/FC ratio) represents a semiquantitative measure of D2 receptor binding in the striatum. Our study sample included six patients treated with haloperidol (3.0-8.0 mg/day orally; one patient with an average of 0.9 mg/day intramuscularly), five patients with benperidol (9.0-15.0 mg/day orally) and nine patients treated with clozapine (200.0-600.0 mg/day orally). Typical neuroleptics (TNs) and atypical neuroleptics (ANs) were significantly di…

AdultMalemedicine.medical_specialtyBipolar DisorderPyrrolidinesNeuroscience (miscellaneous)Benperidolchemistry.chemical_compoundIodobenzamideBasal Ganglia DiseasesDopamineInternal medicineDopamine receptor D2medicineHaloperidolHumansRadiology Nuclear Medicine and imagingChlorpromazineClozapineClozapineAgedNeurologic ExaminationPsychiatric Status Rating ScalesTomography Emission-Computed Single-PhotonDepressive Disorder MajorSchizophrenia ParanoidDose-Response Relationship DrugReceptors Dopamine D2business.industryBenperidolBrainMiddle AgedCorpus StriatumFrontal LobePsychiatry and Mental healthEndocrinologychemistryDopamine receptorBenzamidesDopamine AntagonistsHaloperidolFemalebusinessAntipsychotic Agentsmedicine.drugPsychiatry Research: Neuroimaging
researchProduct

Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: a multicenter, randomized, double-blind study.

2013

The main objective was to compare the mean change in augmentation index of hypertensive patients treated with nebivolol or atenolol.Multicenter, double-blind randomized study conducted in six Spanish centers. We enrolled outpatients between the ages of 40 and 65 years with mild or moderate essential hypertension (systolic blood pressure, SBP ≥ 140 mmHg to ≤ 179 mmHg and diastolic blood pressure, DBP ≥ 90 mmHg to ≤ 109 mmHg after a 2-week run-in placebo period). Patients received nebivolol 5 mg or atenolol 50 mg once daily. At week 3, atenolol could be titrated up to 100 mg qd for non-responders. Additionally, patients not achieving normal blood pressure after 6 weeks could be treated with 2…

AdultMalemedicine.medical_specialtyBlood PressureEssential hypertensionlaw.inventionNebivololHydrochlorothiazideRandomized controlled trialDouble-Blind MethodlawInternal medicineInternal MedicinemedicineHumansBenzopyransAntihypertensive AgentsAgedbusiness.industryGeneral MedicineMiddle AgedAtenololmedicine.diseaseNebivololPulse pressureBlood pressureAtenololEthanolaminesAnesthesiaHypertensionCardiologyAortic pressureFemaleEssential HypertensionCardiology and Cardiovascular Medicinebusinessmedicine.drugBlood pressure
researchProduct